Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe symbols : Jazz save search
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
Published: 2024-03-12 (Crawled : 22:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.44%
H: 0.59%
C: -0.28%
day pharmaceuticals
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-20 (Crawled : 00:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.02%
H: 0.69%
C: -2.01%
conference pharmaceuticals
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.83%
H: 1.11%
C: -0.1%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.32%
H: 0.78%
C: -1.13%
breast cancer pharmaceuticals sabcs potential
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.25%
H: 1.25%
C: 0.99%
pharmaceuticals meeting
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav®
Published: 2023-10-23 (Crawled : 12:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -1.39%
H: 0.09%
C: -2.36%
xywav treatment pharmaceuticals
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
Published: 2023-10-18 (Crawled : 20:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.73%
H: 1.43%
C: 0.62%
world pharmaceuticals
Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023
Published: 2023-04-26 (Crawled : 22:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.33%
H: 0.3%
C: -1.98%
report pharmaceuticals financial results
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance
Published: 2023-03-01 (Crawled : 00:00) - biospace.com/
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: -0.24%
H: 1.31%
C: -2.32%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.4%
H: 1.72%
C: 0.48%
pharmaceuticals year financial results
Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023
Published: 2023-02-15 (Crawled : 23:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.83%
H: 0.86%
C: -0.02%
pharmaceuticals report year financial results
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
Published: 2022-08-03 (Crawled : 00:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.05%
H: 0.24%
C: -0.76%
results
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
Published: 2022-05-12 (Crawled : 18:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.42%
H: 1.54%
C: 0.03%
asco
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -1.4%
H: 0.61%
C: -4.73%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -17.99%
H: 1.48%
C: -7.64%
sunosi therapeutics solriamfetol
Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
Published: 2022-04-20 (Crawled : 23:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.28%
H: 1.05%
C: 0.6%
report results
Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule
Published: 2022-02-02 (Crawled : 13:30) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: 0.0%
fda als application license
U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
Published: 2022-01-03 (Crawled : 23:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.69%
H: 2.14%
C: 2.13%
xywav fda drug orphan drug sodium oxybate
Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -3.5%
H: 0.0%
C: 0.0%
treatment lung cancer cancer
Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results
Published: 2021-08-03 (Crawled : 22:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.45%
H: 0.18%
C: 0.02%
financial results results
National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia
Published: 2021-07-22 (Crawled : 21:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: -1.69%
cancer leukemia
Health Canada Approves Vyxeos the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML)
Published: 2021-07-07 (Crawled : 22:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.31%
H: 0.99%
C: 0.28%
myeloid leukemia risk therapy leukemia acute myeloid leukemia aml
Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc
Published: 2021-06-17 (Crawled : 12:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.62%
H: 0.24%
C: -1.25%
acquired
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.